Effects of ligandrol as a selective androgen receptor modulator in a rat model for osteoporosis-Reference-Cited by-同舟云学术

Effects of ligandrol as a selective androgen receptor modulator in a rat model for osteoporosis

Published:2023-07-06 Issue:6 Volume:41 Page:741-751
ISSN:0914-8779
Container-title:Journal of Bone and Mineral Metabolism
language:en
Short-container-title:J Bone Miner Metab

Author:

Hoffmann Daniel B.,Derout Christoph,Müller-Reiter Max,Böker Kai O.,Schilling Arndt F.,Roch Paul J.,Lehmann Wolfgang,Saul Dominik,Hawellek Thelonius,Taudien Stefan,Sehmisch Stephan,Komrakova Marina

Funder

Deutsche Forschungsgemeinschaft

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Orthopedics and Sports Medicine,General Medicine,Endocrinology, Diabetes and Metabolism

Link

https://link.springer.com/content/pdf/10.1007/s00774-023-01453-8.pdf

Reference49 articles.

1. Osterkamp R (2005) Population developments in Germany until 2050. Chirurg 76:10–18

2. Popp AW, Zysset PK, Lippuner K (2016) Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int 27:1917–1921

3. Reginster JY, Brandi ML, Cannata-Andía J, Cooper C, Cortet B, Feron JM, Genant H, Palacios S, Ringe JD, Rizzoli R (2015) The position of strontium ranelate in today’s management of osteoporosis. Osteoporos Int 26:1667–1671

4. Muchmore DB (2000) Raloxifene: a selective estrogen receptor modulator (SERM) with multiple target system effects. Oncologist 5:388–392

5. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645